EdgeRock Capital’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.43M Buy
1,189
+199
+20% +$203K 0.32% 39
2026
Q1
$912K Buy
990
+54
+6% +$54.7K 0.25% 40
2025
Q4
$1.01M Buy
936
+90
+11% +$86.1K 0.27% 39
2025
Q3
$646K Sell
846
-71
-8% -$52.8K 0.18% 57
2025
Q2
$714K Buy
+917
New +$713K 0.23% 49
2023
Q4
Sell
-407
Closed -$219K 342
2023
Q3
$219K Buy
+407
New +$210K 0.13% 57
2022
Q4
Sell
-179
Closed -$58K 242
2022
Q3
$58K Buy
+179
New +$56.7K 0.03% 96

Other funds holding LLY

EdgeRock Capital's LLY Position: Q2 2026 in Review

EdgeRock Capital increased its Eli Lilly (LLY) stake by 20% in Q2 2026, buying an estimated $203K and bringing the position to 1,189 shares worth $1.43M. The position accounts for 0.32% of the portfolio, ranked #39.

EdgeRock Capital first reported a position in LLY in Q3 2022 and has held it in 7 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • EdgeRock Capital held 1,189 shares of Eli Lilly worth $1.43M as of Q2 2026.
  • EdgeRock Capital bought 199 Eli Lilly shares in Q2 2026, an estimated $203K.
  • Eli Lilly made up 0.32% of EdgeRock Capital's portfolio in Q2 2026, its #39 holding.
  • EdgeRock Capital first reported a position in Eli Lilly in Q3 2022 and has held it in 7 quarters since.
  • 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on EdgeRock Capital's 13F filing for Q2 2026, filed 24 Jul 2026.